Related Experiment Video
Updated: Jan 10, 2026

Author Spotlight: Advancements in Retroperitoneal Approach for Necrotizing Pancreatitis
Published on: March 15, 2024
Developing a Core Outcome Set for blood purification in hypertriglyceridemic acute pancreatitis: a Delphi study
Shengteng Guo1, Haoran Zhu1, Rongzhen Zhao1
1School of Nursing (School of Gerontology), Binzhou Medical University, Binzhou, Shandong, China.
Background:
Early initiation of lipid-lowering therapy is crucial for controlling disease progression and preventing recurrent acute pancreatitis in patients with hypertriglyceridemic acute pancreatitis (HTGP). As a clinically common intervention for HTGP, blood purification enables rapid clearance of serum triglycerides. However, the current absence of a standardized outcome measurement system for blood purification in HTGP hinders systematic therapeutic evaluation by clinicians and further impedes the integration and comparison of research findings. Consequently, this study aims to develop a Core Outcome Set (COS) for blood purification in HTGP, standardizing the assessment of treatment efficacy and enhancing comparability across similar studies.
Methods:
The COS will be developed in accordance with the Core Outcome Measures in Effectiveness Trials (COMET) Handbook, Core Outcome Set-STAndardised Protocol (COS-STAP), Core Outcome Set-STAndards for Development (COS-STAD), and Core Outcome Set-STAndards for Reporting (COS-STAR). First, research team members and a stakeholder panel will be recruited. Outcome indicators relevant to stakeholders will be identified through systematic reviews and interviews. The stakeholder panel and domain experts will then participate in a two-round Policy Delphi process followed by a consensus meeting to discuss and score potential outcomes, ultimately determining the final COS. The finalized COS will be disseminated via a peer-reviewed publication and a checklist to facilitate implementation and promotion.
Discussion:
The COS for blood purification in HTGP will establish a standardized, evidence-based outcome measurement framework. This structured approach will: (1) Enable comprehensive therapeutic evaluation by clinical teams, (2) Enhance precision in disease progression control, (3) Reduce heterogeneity across comparable studies, and may ultimately inform global treatment practices for HTGP.
Standardized Registration Statement:
This study has been prospectively registered with the Core Outcome Measures in Effectiveness Trials (COMET) initiative (ID: 3231; Accessible at: https://www.comet-initiative.org/Studies/Details/3231) and the China Clinical Trial Core Outcome Sets Research Center (ChiCOS) (ID: CHICOS2024000024; Accessible at: https://www.chicos.org.cn/home).
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

